Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.60 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178715 | 1.00 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13738881 | 0.88 | F10 (0.79) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13838775 | 0.88 | F10 (0.79) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13739376 | 0.88 | F10 (0.79) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL455330 | 0.87 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7723004 | 0.87 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13738628 | 0.87 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7723895 | 0.87 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21278838 | 0.87 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL455331 | 0.87 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312320-B2 | Method for synthesizing n-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | HANGZHOU DIKE TECHNOLOGIES CO., LTD. (CN) | 2025-05-27 | — | — | US | claimed |
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | HANGZHOU DIKE TECHNOLOGIES CO., LTD. (CN) | 2022-08-25 | — | — | US | claimed |
| CN-112409286-B | Synthesis method of N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | 杭州迪克科技有限公司 | 2022-08-05 | — | — | CN | claimed |
| EP-4001268-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | Hangzhou Dike Technologies Co., Ltd. (CN) | 2022-05-25 | — | — | EP | claimed |
| CN-112409286-A | Synthesis method of N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | 杭州迪克科技有限公司 | 2021-02-26 | — | — | CN | claimed |
| CN-111265668-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2014-12-25 | — | — | US | claimed |
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | claimed |
| US-12312320-B2 | Method for synthesizing n-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | HANGZHOU DIKE TECHNOLOGIES CO., LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | HANGZHOU DIKE TECHNOLOGIES CO., LTD. (CN) | 2022-08-25 | — | — | US | disclosed |
| CN-112409286-B | Synthesis method of N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | 杭州迪克科技有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-4001268-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | Hangzhou Dike Technologies Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
| CN-112409286-A | Synthesis method of N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | 杭州迪克科技有限公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2021031533-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | 杭州迪克科技有限公司 | 2021-02-25 | — | — | WO | disclosed |
| EP-2521723-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | Enantia, S.L. (ES) | 2012-11-14 | — | — | EP | disclosed |
| US-20120283434-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2012-11-08 | — | — | US | disclosed |
| US-20120283434-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2012-11-08 | — | — | US | disclosed |
| US-20120283434-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2012-11-08 | — | — | US | disclosed |
| WO-2011080341-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080341-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283434-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | F12, VKORC1, CYP2C9 | F10 4/4885CYP1A2 24/4885CYP3A4 18/4885 |
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | CYP3A5, CYP1A2, CYP3A4 | F10 549/4885CYP1A2 2/4885CYP3A4 3/4885 |
| US-12312320-B2 | Method for synthesizing n-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | CYP3A5, CYP1A2, CYP3A4 | F10 549/4885CYP1A2 2/4885CYP3A4 3/4885 |
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | VKORC1, VKORC1L1, F2 | F10 11/4885CYP1A2 16/4885CYP3A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.